1. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia 
Uri Ladabaum, Ajitha Mannalithara 
Gastroenterology 
Volume 151, Issue 3, Pages e6 (September 2016)
DOI: /j.gastro
Copyright © 2016 AGA Institute Terms and Conditions

2. Figure 1
Effectiveness (discounted quality-adjusted life years per person) and cost (discounted dollars per person) for screening strategies. FIT with 100% consistent screening participation and without additional patient support costs was cost-saving compared with no screening. MT-sDNA achieved effectiveness similar to the other strategies given the same levels of patient participation, but it was more costly. Participation rates of 50% consistent screening and 27% intermittent screening are representative of successful organized screening programs, and the results for FIT with these participation rates include patient support costs of $153 per testing cycle.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions

3. Supplementary Figure 1
Schematic of the natural history module in the decision analytic model. The principal health states in the model are normal, small adenomatous polyp, large adenomatous polyp, localized colorectal cancer (CRC-L), regional colorectal cancer (CRC-R), disseminated colorectal cancer (CRC-D), alive after treatment for localized colorectal cancer (s/p CRC-L), alive after treatment for regional colorectal cancer (s/p CRC-R), and dead. Without screening, colorectal cancer is diagnosed and treated (Rx) only after symptoms (Sx) develop.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions

4. Supplementary Figure 2
Effectiveness (discounted QALYs/person) and cost (discounted dollars/person) for screening with MT-sDNA at progressively higher frequencies. Each arrow points to a line segment whose slope is the incremental cost per QALY gained of the shorter vs the longer screening interval that are represented by the 2 points joined by the line segment.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions

5. Supplementary Figure 3
Effectiveness (discounted QALYs/person) and cost (discounted dollars/person) for screening with MT-sDNA at progressively higher frequencies (sensitivity analysis with Medicare costs assumed for all ages). Each arrow points to a line segment whose slope is the incremental cost per QALY gained of the shorter vs the longer screening interval that are represented by the 2 points joined by the line segment.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions

6. Supplementary Figure 4
Effectiveness (discounted QALYs/person) and cost (discounted dollars/person) for screening strategies.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2016 AGA Institute Terms and Conditions